ArticleBlood cancer journal2026
Prognostic impact of morphological lymphocyte counts on aggressive adult T-cell leukemia/lymphoma: Japan ATL nationwide registry analysis.
Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Adult T-cell leukemia/lymphoma (ATL) is a lymphoid malignancy with poor prognosis. Although an increased tumor burden and impaired host immunity are recognized as adverse prognostic factors for aggressive ATL, the prognostic significance of morphologically normal and abnormal peripheral blood lymphocyte counts at the time of diagnosis has not been clarified. We analyzed 638 patients newly diagnosed with aggressive ATL enrolled since 2021 in a nationwide prospective registry across 152 Japanese institutions. Cutoff values derived from receiver operating characteristic curves for survival outcomes identified 860/μL for normal lymphocytes and 15,000/μL for abnormal lymphocytes. Patients with low normal lymphocyte counts had significantly poorer overall survival (OS; P < 0.001) and progression-free survival (PFS; P < 0.001) than those with higher counts. Elevated abnormal lymphocyte counts were significantly associated with shorter PFS (P = 0.004), but not OS (P = 0.496). In multivariate analyses incorporating eight established prognostic factors, a low normal lymphocyte count remained an independent predictor of shorter OS and PFS, whereas a high abnormal lymphocyte count independently predicted shorter PFS. These findings demonstrate that normal and abnormal lymphocyte counts are routinely measured, inexpensive, and rapidly available parameters, highlighting their value as practical and informative prognostic indicators of aggressive ATL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.